Alzheimer’s and Cannabinoids: Research and Clinical Data
Medical cannabis is being studied for some symptoms of Alzheimer’s disease — agitation, broken sleep and a fading appetite — and the results so far are small and mixed. No study shows that it treats or slows the disease in people. Every form acts on the brain and can interact with dementia medicines, so the decision belongs in a conversation with a physician.
Built on peer-reviewed research published from 1994 to 2026: trials in people, observational studies and laboratory work
When Alzheimer’s changes sleep, appetite and behavior
Memory loss is the part of Alzheimer’s everyone expects. What wears a household down is usually something else: the nights, the meals and the moods. These changes often arrive before the hardest memory problems, and they are the ones people most often ask a doctor to help with.
Nights that don’t end
The disease damages the brain’s internal clock. A person who slept soundly for decades starts waking at two in the morning, dressing for work that ended years ago, or pacing the hallway until dawn. Daytime naps grow longer, and the night grows shorter. When someone with Alzheimer’s is not sleeping, the whole home stops sleeping with them.
Sleeping pills are not a simple answer here. Many of them add confusion the next morning and make a fall on the way to the bathroom more likely.
Meals left untouched
Weight loss is common, and it has several causes at once: food tastes different, the person forgets they have not eaten, chewing and swallowing become harder, or the table itself becomes confusing. Yes, Alzheimer’s can cause weight loss — and in the later stages an untouched plate is one of the clearest signs that care needs to change.
Agitation and hallucinations
Restlessness, sudden anger, suspicion and seeing people who are not there are part of the illness, not a choice. They tend to peak in the late afternoon and evening. The medicines usually tried for them — antidepressants, antipsychotics, sedatives — each carry their own risks in an older brain, and a large phase 3 trial of escitalopram for agitation in Alzheimer’s did not beat placebo on its main measure [1]. That trial was not about cannabis; it shows how few good options there are.
What is Alzheimer’s disease?
Alzheimer’s disease is a progressive brain disorder. Two abnormal proteins build up in the brain: amyloid, which clumps into plaques between nerve cells, and tau, which twists into tangles inside them. Nerve cells lose their connections and die, starting in the areas that form new memories and spreading outward over years [2]. That is why a person may forget this morning’s phone call while still remembering their wedding day.
It is common. A 2026 study puts the number of people living with Alzheimer’s disease worldwide at about 50 million [3], and a 2026 review counts 57 million people with dementia of any kind in 2019, with about 153 million people aged 40 and older expected to live with dementia by 2050 [4]. Standard care combines medicines that support memory for a time — cholinesterase inhibitors such as donepezil, and memantine — with newer anti-amyloid antibodies for some people in early stages, plus a great deal of non-drug support [2].
Dementia: the umbrella
What it is: a name for a set of symptoms — memory, thinking and judgment declining enough to disrupt daily life.
What causes it: many diseases, including Alzheimer’s, vascular disease, Lewy body disease and frontotemporal degeneration.
What it tells you: how much help a person needs, not why.
Alzheimer’s: the most common cause
What it is: one specific disease under that umbrella, defined by amyloid plaques and tau tangles.
What causes it: a mix of age, genes and health over a lifetime; the exact trigger is still unknown.
What it tells you: the likely course, and which treatments and trials apply.
Quick answers
Is Alzheimer’s hereditary?
Partly. A small share of cases, usually starting before 65, run in families through single genes. For the common late-onset form, many genes each add a little risk. In the large genetic analysis above, people whose combined genetic score was in the top tenth had about twice the odds of advanced tau spread in the brain (odds ratio 2.05, 95% CI 1.47–2.85) compared with people in the middle [6]. Having a parent with Alzheimer’s raises your risk; it does not make the disease certain.
How is it diagnosed? Biomarkers, lab tests and scans
A doctor starts with a history, memory and thinking tests, and blood work to rule out look-alikes such as low vitamin B12 or thyroid problems. Biomarkers — measurable signs of the disease itself — confirm it: amyloid and tau in spinal fluid, PET scans that show amyloid or tau in the brain, and, increasingly, blood tests for the same proteins. MRI or CT rules out strokes and tumors [2].
Can Alzheimer’s come on suddenly?
Alzheimer’s itself develops slowly, over years. Confusion that appears over hours or days should be treated as something else until a doctor has checked — most often delirium triggered by an infection such as a urinary tract infection, dehydration, a new medicine or pain. Sudden confusion is a reason to call a doctor the same day, not to wait.
Alzheimer’s stages and the symptoms that change
Doctors usually describe three stages: early (mild), middle (moderate) and late (severe). The lines between them are blurry, people move through them at very different speeds, and the middle stage is often the longest [2]. The table below follows one symptom at a time across all three.
What are you seeing most?
Pick one to compare it across the stages; nothing here tells you which stage someone is in.
| Stage | Memory & thinking | Behavior & sleep | Eating & weight | Daily care |
|---|---|---|---|---|
| Early (mild) | Forgets recent conversations, repeats questions, loses words and objects; planning and money take longer. | Withdrawal, low mood or anxiety; sleep starts to fragment in some people. | Usually unchanged; may skip meals when living alone. | Lives independently with reminders; driving and finances need watching. |
| Middle (moderate) | Confused about time and place, may not recognize familiar people, gets lost in known places. | Agitation, suspicion, wandering, evening restlessness, day–night reversal; hallucinations can begin. studied in cannabinoid research | Forgets to eat or eats repeatedly; tastes change; weight may start to fall. studied in cannabinoid research | Needs help choosing clothes, bathing and taking medicines; often not safe alone. |
| Late (severe) | Little or no speech, cannot follow conversation, loses awareness of surroundings. | Agitation may persist or fade into apathy; sleeps much of the day. studied in cannabinoid research | Trouble chewing and swallowing; marked weight loss and risk of choking. studied in cannabinoid research | Needs help with every daily activity, often round the clock; many families consider nursing home or memory care at this point. |
The last stage is the one people search for most, and the one where symptom relief matters most. It is also where the body is most fragile, which is why any added medicine, cannabis included, needs a physician’s eye on the full list.
Could medical cannabis be worth discussing for these symptoms?
Fifteen short questions about the diagnosis, the symptoms and the medicines already in use. Your answers stay on this page and show what to bring to a physician.
15 questions · about a minute · your answers stay in this browser
Can cannabis help with Alzheimer’s symptoms?
Possibly, for some symptoms in some people — but the evidence comes from a handful of small trials with mixed results, so it is a reasonable question to raise with a physician rather than an established treatment. Reviewers who looked at the cannabinoid trials in Alzheimer’s describe the field the same way: promising, not ready for routine use [7][8].
Three symptoms have drawn most of the attention. Choose one to see what was tested.
Agitation
Dronabinol, a prescription form of THC, raised step by step to at most 10 mg a day in a trial in people with Alzheimer’s and agitation [8].
Small trials with different products and doses; results point in different directions [8].
The most-studied symptom, and still unsettled. Drowsiness was common in the trials.
Sleep
Mostly as a side measure in behavior trials. Sleepiness shows up in safety reports on THC and CBD in older adults [9].
No trial listed here was built around sleep in Alzheimer’s.
Feeling drowsy is not the same as sleeping better at night. Read more on whether cannabis is good or bad for sleep.
Appetite & weight
Dronabinol is FDA-approved for weight loss and poor appetite in people with AIDS [10]; in Alzheimer’s it has been studied mainly for behavior.
No trial in this list measured weight in Alzheimer’s as its main goal.
A plausible reason to ask, not a known benefit in dementia.
How big is the effect?
Honestly, nobody can say yet. A chart of effect sizes needs several trials that report the same outcome with a margin of error, and for cannabinoids in Alzheimer’s that set does not exist. The clearest single number is about how small the trials are.
What this means in practice: if agitation or poor sleep is the problem, a physician may consider cannabinoids alongside — not instead of — the usual steps, and will weigh them against drowsiness, falls and the medicines already on the list.
Can cannabis stop or reverse Alzheimer’s?
No. There is no evidence in people that cannabis or any cannabinoid stops, slows or reverses Alzheimer’s disease, and no trial has shown that memory gets better and stays better. Can Alzheimer’s get better on its own? The disease itself does not, although a bad stretch caused by infection, poor sleep or a medicine side effect can improve once that cause is treated.
The hopeful headlines come from animals. Researchers are interested because the brain’s own cannabinoid system changes in Alzheimer’s: post-mortem brain tissue from people with the disease showed less of the CB1 receptor, the main target of THC, in the hippocampus and two cortical regions [3].
In mice
What was tested: URB597, a drug that raises the body’s own cannabinoid anandamide, given in the nose at 5 mg/kg for 5 months to male Tg2576 mice bred to build amyloid plaques [11].
What changed: fewer amyloid plaques and less brain inflammation; in a separate study, CBD at 100 mg/kg for 6 weeks in 22 male mice restored a social memory test [12].
What it means: a lead worth testing, in animals only.
In people
What was tested: THC, CBD and combinations, mostly for agitation, and one low-dose THC–CBD extract for thinking and memory in 28 patients [7].
What changed: no trial has shown slowing of the disease; results on symptoms are mixed.
What it means: cannabis is a symptom question, not a disease-modifying treatment.
Animal results do not transfer to people: mouse models carry one engineered form of the disease, and doses per kilogram do not translate to a human dose.
How the mouse study was done
In animal studies, the team blocked FAAH, the enzyme that breaks down anandamide, either by removing its gene or with URB597. More anandamide switched on CB1 receptors, which silenced the gene for BACE1 — the enzyme that cuts the amyloid precursor into the sticky fragments that form plaques. Plaque density fell (p = 0.0002) and soluble amyloid-beta 42 dropped, and a CB1 blocker undid the effect [11]. Only male mice were used, so the result may not even hold for female animals.
What the research shows, from strongest to weakest
Not all studies count the same. A randomized trial in people answers “does it work?” far better than a mouse experiment or a survey. Here is what exists for cannabinoids and Alzheimer’s at each level, with the background studies clearly marked.
| Level | What exists for Alzheimer’s | What it can and cannot tell you |
|---|---|---|
| Trials in people | Small randomized trials of THC, CBD and dronabinol, mostly for agitation; one THC–CBD extract trial analyzed 28 patients [7][8]. A large escitalopram trial (173 people, 12 weeks) is a background comparison, not a cannabis study [1]. | Can show a symptom effect and side effects; too small and short so far to show a clear benefit. |
| Observational studies | Large records studies of cannabis use and thinking in older adults; in veterans, cannabis use disorder was linked to a higher rate of later cognitive disorders (hazard ratio 3.26, 95% CI 2.91–3.65) [13]. Genetic studies of risk are background [5]. | Shows links, not cause; heavy problem use is not the same as supervised medical use. |
| Animal and lab work | Mouse and cell studies of CBD, THC and the FAAH enzyme, with less plaque and inflammation [11][12]. | Explains why scientists are interested; says nothing yet about patients. |
Browse the studies yourself
Every study cited on this page, in plain words. Neutral and negative results are included.
A low-dose THC–CBD extract for thinking and memory
A placebo-controlled trial analyzed 28 patients, short of the 37 it needed; the results were mixed and the reviewer judged it not ready for prescribing [7].
Escitalopram for agitation in Alzheimer’s
An antidepressant plus support was no better than placebo on the main measure at 12 weeks (p = 0.28), and falls were more frequent on the drug [1].
Fewer cannabinoid receptors in Alzheimer’s brains
CB1 receptor levels were lower in the hippocampus and two cortical regions of people who had Alzheimer’s, and in mouse models [3].
Past cannabis use and thinking in adults over 60
Links between earlier cannabis use and later test scores were mixed, pointing neither clearly to harm nor to benefit [14].
Cannabis use disorder and later cognitive problems
Veterans with a cannabis use disorder developed cognitive disorders more often (hazard ratio 3.26, 95% CI 2.91–3.65), with added risk after brain injury [13].
The body’s own cannabinoids and memory in older adults
Blood levels of some endocannabinoids tracked with thinking scores in dementia-free adults, mostly in women and in carriers of the APOE ε4 gene [15].
How psychiatric patients see cannabis after legalization
After legalization, fewer named the law as their reason to avoid cannabis (11.2% before, 1.7% after), but worries about mental health stayed high [16].
The cost of memory problems for older Medicare patients
Cognitive impairment added about $6,883 a year in health costs for women and $7,276 for men [17].
Learning you have brain amyloid
Telling cognitively healthy people that a scan showed elevated amyloid was not linked to long-term suicidal thoughts [18].
Estimating brain synapse loss from an ordinary MRI
A deep learning model produced synapse-density PET images from standard MRI scans, a possible cheaper way to follow the disease [19].
Cannabinoids in Alzheimer’s: from animals to patients
Animal results for CBD and THC are encouraging, but human trials are few, small and use different products; one trial titrated dronabinol to 10 mg a day [8].
Why dose matters so much in the aging brain
THC and CBD act differently at low and high doses in older brains, and CBD can raise levels of other medicines by blocking liver enzymes [9].
Medicinal plants for Alzheimer’s
Plant compounds show many effects in the lab, but human evidence is thin; the review warns about herb–drug interactions in older adults on many medicines [20].
Diet supplements tested in Alzheimer’s trials
Across nine widely studied dietary compounds, late-stage trials showed no consistent benefit for thinking [4].
Cannabis use among people caring for older adults
Some people looking after an older relative use cannabis to cope with stress; younger ones and those with anxiety or depression were more likely to start or increase use [21].
Natural products against amyloid and inflammation
A survey of plant compounds and new delivery systems aimed at amyloid clumping and brain inflammation, still mostly in the lab [22].
Old drugs that might be repurposed for Alzheimer’s
Experts ranked the shingles vaccine, sildenafil and riluzole as top candidates to test; cannabinoids were not among the priorities [23].
91 genetic regions tied to Alzheimer’s and related dementias
Sixteen of the regions were new; the genes point to amyloid, tau, fats, immunity and the brain’s immune cells [5].
A genetic score that predicts brain changes
People with the highest genetic scores had about twice the odds of advanced tau (OR 2.05, 95% CI 1.47–2.85) and of heavy amyloid plaques (OR 1.96, 95% CI 1.39–2.78) [6].
Alzheimer’s risk genes across ancestries
Studying people of several ancestries found new risk regions that single-ancestry studies had missed [24].
Does substance use speed up biological aging?
Genetic signals for cannabis use disorder were tied to small changes in aging measures, far smaller than those for tobacco [25].
Blocking FAAH in mice with amyloid plaques
Raising the brain’s own anandamide cut plaque density and inflammation in male mice over 5 months [11].
High-dose CBD in Alzheimer’s model mice
CBD at 100 mg/kg a day for 6 weeks restored a social memory test, with mixed results on other measures [12].
A blood pressure drug and brain inflammation in mice
Valsartan lowered inflammation and amyloid-beta 42 (by 53%) in mice, partly through the endocannabinoid system [26].
No studies of this type are cited on this page.
What kinds of studies is this evidence built on?
How to read it: each row is one kind of study, and the bar shows how many published studies on cannabinoids and Alzheimer’s are of that kind. Stronger designs are at the top. Gray bars are commentary, animal and lab work, which cannot answer whether something helps patients.
Show as a table
| Design | Studies |
|---|---|
| Meta-analyses | 12 |
| Systematic reviews | 11 |
| Randomized trials | 16 |
| Crossover randomized trials | 4 |
| Other clinical trials | 4 |
| Cohort studies | 14 |
| Case-control studies | 4 |
| Cross-sectional studies | 6 |
| Surveys | 1 |
| Case reports | 5 |
| Narrative reviews | 133 |
| Animal studies | 65 |
| Cell and lab studies | 51 |
| Who was studied | Studies |
|---|---|
| People in clinical trials | 54 |
| People observed, not treated | 285 |
| Whole populations | 9 |
| Animals | 72 |
| Cells and molecules | 37 |
| Not classified | 65 |
Which cannabinoids have been studied?
“Cannabis” in these studies means very different things: THC, the compound that changes how you feel; CBD, which does not cause a high; products that mix the two; and prescription medicines made from or modeled on THC. A result for one does not carry over to another — the drowsiness of THC says nothing about a CBD-only oil, and CBD’s interactions say nothing about THC.
| Substance | What was studied | Design | What came out |
|---|---|---|---|
| Dispensary products (available with a medical card where your state allows) | |||
| THC | Agitation and behavior in people; amyloid and tau in mice, including an ultra-low 0.002 mg/kg dose given in the nose [8]. | Small trials; animal studies | Mixed in people. In animals, effects flip with dose: a high 10 mg/kg dose activated brain inflammation cells [9]. |
| CBD | Amyloid build-up and memory in mouse models, from 5 mg/kg up to 100 mg/kg a day [8][12]. | Mostly animal studies | Less amyloid and better memory tests in mice; almost no data in patients. Blocks liver enzymes that clear other medicines [9]. |
| THC + CBD combinations | A low-dose balanced extract for thinking and memory; a 26-week low-dose oral THC + CBD trial [7][8]. | Small randomized trials | Mixed; the cognition trial was smaller than planned [7]. |
| Prescription medicines (FDA-approved, by prescription, not through a card) | |||
| Dronabinol (Marinol, Syndros) | Agitation in Alzheimer’s, titrated up to 10 mg a day in one trial [8]. | Clinical trials | Not approved for dementia; approved for chemotherapy nausea and AIDS-related weight loss [10]. |
| Nabilone (Cesamet) | One of the synthetic cannabinoids tested for behavior symptoms in dementia. | Small trials | Not approved for dementia; approved for chemotherapy nausea [10]. |
Ways to use cannabis: what each form avoids
Cannabis is not only smoked. People also vape it, swallow it as capsules, gummies or oils, hold drops under the tongue, or apply it to the skin. Each form avoids some risks and keeps others, and none of them is a safe default for an older person with dementia. This section explains the differences; it does not recommend a form.
How is it used, or how would it be?
Choose the closest; most people combine more than one.
Specific to smoking
Joints, blunts, pipes and bongs burn plant material, and the smoke irritates the throat and lungs. The effect starts within minutes and is hard to measure in milligrams. Lighting and holding a joint is also a burn and fire risk for someone who is confused.
Specific to vaping and dabbing
Dry-herb vaporizers, oil pens and cartridges avoid burning, but hot vapor still travels the same airways. Concentrates used for dabbing, such as wax or shatter, are very strong, which makes the dose even harder to control.
Shared devices
A pipe, vape or joint passed between people also passes on colds and other infections — a real concern for someone frail.
Specific to edibles and capsules
Gummies, chocolates, drinks, capsules and swallowed oils avoid smoke entirely. They act slowly — often an hour or more — and last for hours, and the liver processes them first: a 2026 review puts the share of swallowed THC that reaches the blood at only about 6% [9]. The classic mistake is a second piece “because the first did nothing,” which an older person may not remember having taken at all.
Specific to tinctures and sprays
Drops held under the tongue and mouth sprays avoid the lungs and are measured by the drop or spray. Part of the dose is still swallowed, and some pharmaceutical-grade oral solutions contain alcohol, which matters with certain medicines (see interactions).
Specific to topicals and patches
Creams and balms act mainly where they are applied and are not a way to treat brain symptoms. Transdermal patches are different: they deliver cannabinoids into the bloodstream, so their effects on the brain and on other medicines count the same as any other form.
Specific to prescription cannabinoids
Dronabinol and nabilone are capsules with an exact dose, prescribed by a doctor and filled at a pharmacy, not bought with a medical card. They are not approved for dementia [10], and they carry the same drowsiness and fall risks as THC.
True of every form
- THC can cause sleepiness, confusion and dizziness, which raise the risk of falls.
- It can add to the effect of sedatives, sleeping pills and some dementia medicines.
- Whatever reaches the blood is handled by the liver and can change levels of other drugs.
- No driving after use.
Choosing a form is a conversation for the appointment.
All forms as a table
| Form | What it avoids | What remains |
|---|---|---|
| Smoking | Delay in onset | Smoke in the airways, burn risk, shared devices, hard-to-measure dose, all effects of THC |
| Vaping & dabbing | Burning plant material | Hot vapor in the airways, very strong concentrates, shared devices, all effects of THC |
| Edibles & capsules | Smoke and vapor, shared devices | Slow, long effect, risk of a repeat dose, liver processing, interactions |
| Tinctures & sprays | Smoke and vapor, shared devices | Effects on the brain, partly swallowed dose, alcohol in some solutions, interactions |
| Topicals | Most effects on the brain | Skin reactions; no effect on brain symptoms |
| Transdermal patches | Smoke, vapor and swallowing | Effects on the brain, interactions, the same fall risk |
| Prescription cannabinoids | Unknown product content | Drowsiness, dizziness, interactions; not approved for dementia |
What science doesn’t know yet
The gaps are not a footnote here; they are most of the story. Researchers who wrote about these studies list the same problems again and again.
- Trials are too small. The THC–CBD cognition trial analyzed 28 patients when 37 were needed to detect a real difference [7]. Even the much larger escitalopram trial enrolled 173 of its planned 392 [1].
- Trials are short. Most last weeks, while Alzheimer’s unfolds over years, so long-term benefit and harm are unknown [20].
- No standard dose or product. Studies use different extracts, ratios and doses, which makes them hard to compare or to copy in real life [9].
- Few studies in older adults themselves. Direct trial data in people of the age most affected are limited [9].
- Mice dominate. Most evidence is still from animals and cells [20], and some key experiments used only male mice [11].
- Mixed patients. People in trials differ in stage and symptoms, which can hide a benefit in one group or a harm in another [7].
Safety for older adults
The same side effect weighs more in an 80-year-old with dementia than in a healthy 40-year-old. A frail person has less reserve: brief dizziness can become a hip fracture, and mild confusion can become a night of distress. Reviewers specifically warn against early, unsupervised use of unregulated cannabis products in Alzheimer’s care because of sleepiness and paranoia in this frail group [7][8].
Drowsiness and sedation
The most common effect reported in older adults taking THC or CBD [9]. It can be mistaken for “better sleep” while daytime function drops.
Confusion and disorientation
Reported with cannabinoids in older adults [9]. In someone already confused, it can be hard to tell the drug from the disease.
Paranoia
Reported in trials in people with Alzheimer’s [7]. Suspicion is already part of the illness, and THC can deepen it.
Falls
Sleepiness, dizziness and low blood pressure on standing all add up. Falls were also more frequent on the antidepressant tested for agitation [1] — any added medicine deserves this question.
Dizziness
Reported, especially when standing up quickly or after a larger dose. Getting up at night is the riskiest moment.
Driving
THC slows reaction time. Anyone using it should not drive, and many people with Alzheimer’s should already have stopped.
Heart rhythm deserves a mention too. In the escitalopram trial for agitation, prolongation of the QTc interval (a change in heart rhythm seen on an ECG) was a reason for caution [1]; if you have a known rhythm problem, any medicine added for agitation, cannabis included, needs a physician’s review. The medicine list is covered in drug interactions to discuss with a doctor.
Drug interactions to discuss with a doctor
Open each one. This is what the studies recorded, not a complete list.
Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) mechanism only
Some plant compounds, cannabinoids among them, may add to the cholinergic side effects of these memory medicines — nausea, slow heart rate, vivid dreams [20]. This is based on how the drugs work, not on patient data. Do not stop a memory medicine to try cannabis.
Benzodiazepines and other sedatives mechanism only
Lorazepam, alprazolam, sleeping pills and similar drugs may add their sedation to cannabis [20]. Together they raise the risk of confusion, breathing problems and falls. More on mixing cannabis and Xanax.
Clobazam clinical data
Adding CBD raised the active form of this seizure medicine four- to five-fold by blocking the liver enzymes that clear it [9]. Seizures can occur in Alzheimer’s, so this pairing is not hypothetical.
Disulfiram or metronidazole clinical data
Some pharmaceutical-grade oral cannabinoid solutions contain alcohol, and they are contraindicated with these two drugs [9].
Many medicines at once (liver enzyme interactions) clinical data
CBD and THC are processed by the CYP450 liver enzymes that also handle many antidepressants, antipsychotics, blood thinners and heart drugs. Reviewers urge caution in older adults on several medicines because blocked enzymes change how those medicines are cleared [9], and they ask for monitoring of herb–drug interactions in this group [20]. The studies here do not name individual antipsychotics or antidepressants; your physician checks those one by one.
Bring the complete list — prescriptions, over-the-counter sleep aids, supplements and anything taken “only sometimes” — to the appointment. That list, more than the diagnosis, decides whether cannabis is reasonable to try.
Who should not use cannabis for this
For some people the answer is “not now” or “not at all,” whatever the symptom. Trials in this field routinely exclude these groups, so there is no evidence of safety for them.
- A history of psychosis — hallucinations or delusions not explained by dementia; THC can worsen them. See cannabis and psychosis. Studies of cannabis attitudes even exclude these patients [16].
- Heart rhythm problems, especially a known long QTc, when agitation medicines are already in use [1].
- Several sedating medicines already — benzodiazepines, sleeping pills, opioids [20].
- Frequent falls in recent months.
- Pregnancy or breastfeeding — trials exclude it, and THC passes to the baby.
- New, unexplained confusion that has not yet been checked for infection, dehydration or a medicine problem.
Talk to a licensed physician about whether any of these apply
Is Alzheimer’s a qualifying condition for a medical card?
It depends on your state. Every medical cannabis program keeps its own list of qualifying conditions, and a physician has to match your diagnosis to that list, not to a symptom. Some programs name Alzheimer’s disease outright. Others do not use the word but cover conditions that often come with it, and some let a physician certify any condition they judge debilitating.
The lists change as legislatures and health departments update them, so the current wording for your state is the one that counts. The physician confirms it at the evaluation, using your records.
Alzheimer’s is named in your state
The simplest case. Bring a record of the diagnosis — a neurologist’s or primary care note — and the physician evaluates you against that listed condition.
A condition you also have is listed
Chronic pain, insomnia, anxiety or seizures may be on the list even where Alzheimer’s is not. What counts is a diagnosis in your records, not a symptom alone.
Neither is on the list
A card may not be available yet where you live. Some states let physicians certify other debilitating conditions or accept petitions to add new ones.
What else has a doctor diagnosed?
State lists name diagnoses, not symptoms — pick what is in your records.
Insomnia: a diagnosed sleep disorder is listed in some programs and is often recorded alongside Alzheimer’s. Read insomnia and medical cannabis.
Anxiety: several states list anxiety disorders or accept them under broader wording. Read anxiety and medical cannabis.
Depression: fewer states list it, and THC can affect mood in both directions. Read depression and medical cannabis.
Chronic pain: the most widely listed condition across state programs. Read chronic pain and medical cannabis.
Seizures: seizure disorders are on most lists; note the clobazam interaction above. Read seizures and medical cannabis.
None of these: then the decision rests on your state’s wording and the physician’s judgment. Start with your state’s medical marijuana laws.
Medical card or recreational purchase
In states with adult-use sales, adults can buy without a card. A card still changes several things, though the details are set state by state.
| Aspect | With a medical card | Recreational |
|---|---|---|
| Taxes | Often lower; some states waive part of the cannabis tax for patients | Full state and local cannabis taxes |
| Purchase and possession limits | Often higher; depends on your state | Set for adult-use buyers |
| Products | Access to medical dispensaries and, in some states, medical-only products | Adult-use product range |
| Age | Patient age rules set by each program | Adult-use age limit set by the state |
| Physician involvement | A licensed physician reviews your conditions and medicines | None |
| Document | State card or recommendation, recorded in a confidential registry | Government ID only |
Will a card save you money?
It can, but only where your state taxes patients less than recreational buyers, and the amount depends on your state’s tax rates and how much you buy. Weigh that against the evaluation fee and any state registration fee. The breakdown is in medical vs. recreational cannabis taxes, and the wider differences in medical and recreational cannabis compared.
What the program in your state involves
Qualifying is the first of two steps. In most states a physician’s recommendation is followed by registration with the state health department, which issues the card and enters you in a confidential patient registry; in a few, the recommendation itself is what a dispensary asks for. Purchases happen at licensed dispensaries, some of which deliver, and products there are lab-tested and labeled with their THC and CBD content.
Many state laws also let a patient name a registered caregiver who may buy and handle products on their behalf; who qualifies and how to register is set by each state. Cards from one state are not automatically valid in another — see which states accept out-of-state cards. Possession limits, home growing and taxes are listed state by state on the laws and regulations pages.
What this means if you are considering it
A good evaluation is a conversation about one or two specific symptoms, the medicines already in use and what would count as “better.” It goes faster and safer when the facts are on the table.
What to bring to the appointment
Tap each item as you get it ready.
Questions worth asking
- Which of my current medicines could interact, and what would we watch for?
- THC, CBD or both — and why that choice for this symptom?
- How would we know within a few weeks whether it is helping?
- What should make us stop right away?
- Who should I call if confusion or drowsiness gets worse?
An evaluation makes sense if
- A specific symptom — agitation, sleep, appetite — has not settled with the usual steps.
- Your full medicine list can be reviewed.
- Someone at home can keep track of doses.
- Your state’s program covers your diagnosis or a related one.
It is not the right step if
- The hope is to stop or reverse memory loss.
- Confusion is new and has not been checked.
- There have been several recent falls.
- There is a history of psychosis.
This page summarizes published research for education. It does not replace a physician’s advice. Cannabis does not treat Alzheimer’s disease or slow it in people, and older adults taking several medicines face a higher risk of interactions.
How to get a medical card for Alzheimer’s online
Everything happens online, so there is nowhere to travel. Four steps take you from the first form to a card in your hand.
Fill in the intake form
Your state, your diagnoses and your current medicines. Have the record of the Alzheimer’s diagnosis ready to upload.
See a physician licensed in your state
A one-on-one appointment online. You agree on the time with the physician; keep an hour free rather than a minute.
Receive your signed recommendation
If the physician approves, the signed recommendation arrives in your account after the appointment.
Register with your state
Where required, you submit the recommendation to the state program, which reviews it and issues the card.
What you end up with
Across 250 reviews from patients in the states where we are licensed. We do not sort them by score and do not hide the low ones.
- 150,000+patients evaluated — everyone who has been through an appointment with us, in every state where we are licensed
- Since 2017doing only this: online evaluations for medical cannabis programs, and nothing else on the side
A recommendation from a physician licensed where you live, and — once your state registers it — a card that lets you buy at licensed dispensaries. Your documents stay in your account and documents, and how the medical card works explains the evaluation in detail. The physicians who see patients are listed on our physicians page.
Programs for veterans and for people with low income are available in some states.
Questions people ask about Alzheimer’s and cannabis
Can Alzheimer’s kill you, and what is the life expectancy?
Yes. Alzheimer’s shortens life, usually through what it does in the late stage: trouble swallowing leads to pneumonia, immobility leads to infections and falls. How long a person lives after diagnosis varies widely with age at diagnosis and other health conditions; many people live for years, and the middle stage is often the longest [2]. Cannabis has not been shown to change that course.
Can Alzheimer’s get better or go away on its own?
No. The disease itself progresses. A person can have better weeks after an infection is treated, a medicine is changed or sleep improves, which is why sudden worsening always deserves a check-up.
Why does Alzheimer’s sometimes not start with forgetfulness?
Memory trouble is the classic first sign, but families often notice something else first: a change in mood or personality, poor judgment with money, getting lost while driving, or struggling to find words. Some less common forms of Alzheimer’s begin with problems in vision, language or planning rather than memory.
Are hallucinations part of Alzheimer’s?
They can be, usually in the middle and late stages — seeing people or animals that are not there. New hallucinations should also be checked for infection, poor eyesight or a medicine side effect. THC can cause or worsen hallucinations and paranoia, so this is a point to raise before any cannabis product.
Is CBD alone safe with dementia medicines?
Not automatically. CBD does not cause a high, but it blocks liver enzymes that clear many medicines, and with clobazam it raised the active drug four- to five-fold [9]. No study here tested CBD with donepezil or memantine directly. Show the physician the CBD product and the full medicine list.
What about delta-8 THC or CBD products sold without a card?
Hemp-derived products sold in shops and online are often less tightly regulated than dispensary products, and labels may not match what is inside. Delta-8 THC acts much like regular THC, with the same drowsiness, confusion and interaction risks. Reviewers specifically warn against unregulated products in Alzheimer’s care [7].
Can medical cannabis be used in a nursing home or memory care?
That is up to each facility and the law in its state. Many facilities have a written policy, and some do not allow cannabis on site at all, even with a card. Ask the facility in writing before anything is brought in, and make sure its staff have the full medicine list.
Can I use my card in another state?
Sometimes. Reciprocity — one state honoring another state’s card — exists in some states and not others, and rules for visitors vary. Check which states accept out-of-state cards and traveling with cannabis before a trip.
What if my card is lost?
Most states let you request a replacement from the program that issued it. The steps are in what to do if your card is lost and the medical card FAQ.
How do I renew my medical card?
Cards expire on a schedule your state sets, and renewal means a repeat evaluation with updated medicines and a new recommendation. Bring any changes in diagnosis or prescriptions since last time. See how the medical card works, or choose your state from the list at the top of this page.
How much does it cost, and what if I’m not approved?
The evaluation fee for your state is shown before you pay; a state registration fee, where one exists, is paid to the state separately. Whether a recommendation is issued is the physician’s medical decision. Details for both are on how the medical card works.
Is an online evaluation legitimate?
Yes, where state law allows telemedicine for medical cannabis evaluations. The appointment is with a physician licensed in your state, one-on-one, and the recommendation is the same document an in-person visit would produce.
Who finds out? Privacy, firearms and work
Privacy: your medical records are protected under the HIPAA Privacy Rule [27], and state patient registries are confidential; dispensaries and law enforcement can usually check only whether a card is valid.
Firearms: federal law bars anyone who is an “unlawful user” of a controlled substance from having a firearm [28], and cannabis remains federally controlled, so a state card does not change the federal rule.
Work: employment protections for card holders differ by state, and many employers can still enforce drug-free policies. Read your state’s rules on the laws and regulations pages.
More research on cannabis and Alzheimer’s disease
This page cites a selection of studies. Our research library holds every study we track on cannabis and Alzheimer’s disease, from laboratory work to clinical trials, and lets you filter them by cannabinoid, study type and year.
- studies
- 1,500+
- in people
- 510+
- clinical trials
- 94
Related brain and nervous system conditions
Alzheimer’s often travels with other diagnoses, and some of them are on more state lists. Each page below covers its own research and qualifying rules.
Alzheimer’s resources and latest research
For background on how cannabis works in the body, and for new articles as research comes out:
References
28 sources
- 1. Escitalopram for agitation in Alzheimer’s dementia: a randomized controlled phase 3 trial. DOI: 10.1038/s41591-025-03569-y PMID: 40133524
- 2. National Institute on Aging. Alzheimer’s Disease Fact Sheet. 2023.
- 3. Reduced CB1 Cannabinoid Receptor Expression in Alzheimer’s Disease and Transgenic Mouse Models. DOI: 10.1002/agm2.70080 PMID: 42130756
- 4. Dietary Bioactives in Alzheimer’s Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies. DOI: 10.3390/nu18060907 PMID: 41901082
- 5. Consensus meta-analysis of genome-wide association studies for Alzheimer’s disease and related dementias. DOI: 10.1038/s41588-026-02583-1 PMID: 42237039
- 6. Consensus meta-analysis of genome-wide association studies for Alzheimer’s disease and related dementia. DOI: 10.1101/2025.10.20.25338060 PMID: 41282675
- 7. Cannabinoids for Alzheimer’s disease: A promising trial, although not yet ready for the prescription pad. DOI: 10.1177/13872877261452183 PMID: 42216668
- 8. Cannabinoids in Alzheimer’s disease: animal-human evidence and clinical pharmacology challenges. DOI: 10.3389/fnbeh.2026.1833021 PMID: 42211879
- 9. Navigating dose-effect complexities and challenges in cannabinoid therapy for aging-related neurobiological changes. DOI: 10.3389/fphar.2026.1794928 PMID: 42292844
- 10. U.S. Food and Drug Administration. FDA and Cannabis: Research and Drug Approval Process. 2023.
- 11. Fatty-acid amide hydrolase inhibition mitigates Alzheimer’s disease progression in mouse models of amyloidosis. DOI: 10.1111/febs.17403 PMID: 39822137
- 12. Effects of Chronic 100 mg/kg Cannabidiol Treatment in Male Double Transgenic APPSwe/PS1∆E9 Mice. DOI: 10.3390/ph19030374 PMID: 41901221
- 13. Cannabis use disorder contributes to cognitive dysfunction in Veterans with traumatic brain injury. DOI: 10.3389/fneur.2024.1261249 PMID: 38292293
- 14. History of cannabis use and cognitive function in older adults: findings from the UK biobank. DOI: 10.1093/aging/afaf319 PMID: 41189327
- 15. Circulating Endocannabinoids and Cognitive Function in Older Adults. DOI: 10.14336/AD.2024.1427 PMID: 39812547
- 16. Attitudes of Patients with Non-Psychotic Mental Disorders Towards Cannabis After Its Legalization-Comparison with Patients Before Legalization. DOI: 10.3390/brainsci16070730 PMID: 42512504
- 17. Effects of Functional Impairments and Frailty on the Association of Cognitive Impairment with Total Healthcare Costs: A Prospective Multi-cohort Study. DOI: 10.1007/s11606-025-10073-z PMID: 41366620
- 18. Disclosure of elevated amyloid status is not associated with long-term suicidality in a preclinical AD trial. DOI: 10.1002/alz.14623 PMID: 39988989
- 19. Generating synthetic brain PET images of synaptic density based on MR T1 images using deep learning. DOI: 10.1186/s40658-025-00744-5 PMID: 40163154
- 20. Medicinal Plants and Their Bioactive Phytochemicals as Emerging Therapeutic Strategies for Alzheimer’s Disease: An Integrative Review of Preclinical and Clinical Evidence. DOI: 10.1155/sci5/6124916 PMID: 42382677
- 21. Cannabis Use Among Caregivers of Older Adults: A Systematic Literature Review. DOI: 10.1177/30495334261426511 PMID: 41767904
- 22. Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s Disease: Advances and Future Directions. DOI: 10.3390/cells15030295 PMID: 41677657
- 23. Drug repurposing for Alzheimer’s disease: a Delphi consensus and stakeholder consultation. DOI: 10.1186/s13195-025-01895-4 PMID: 41250235
- 24. Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies known and novel cross-population and ancestry-specific associations as novel risk loci for Alzheimer’s disease. DOI: 10.1186/s13059-025-03564-z PMID: 40676597
- 25. Leveraging Genomic Data to Examine the Causal Impact of Alcohol, Tobacco, Cannabis, and Opioid Use on Biological and Cognitive Aging. DOI: 10.1111/adb.70066 PMID: 40653731
- 26. Valsartan Mitigates LPS-Induced Neuroinflammation and Cognitive Deficits via Modulation of RAS-ECS Crosstalk in Mice. DOI: 10.1007/s12035-026-05728-9 PMID: 41820755
- 27. U.S. Department of Health and Human Services. The HIPAA Privacy Rule. 2024.
- 28. Legal Information Institute, Cornell Law School. 18 U.S. Code § 922 — Unlawful acts. 2024.